OnDemand: January 2024 Grand Rounds - Present and Future of Anti-Obesity Medication

Create Account

Availability

On-Demand

Cost

Member: $0.00

Non-Member: $50.00

Credit Offered

1 AMA PRA Category 1 Credit

This presentation will provide an update on the rapidly evolving field of obesity pharmacotherapy and its role in comprehensive obesity care.

1. Learners will be aware of medications for obesity treatment that have recently been FDA approved or are currently in clinical trials.
2. Learners will understand which patients are good candidates for specific anti-obesity medications.
3. Learners will be able to apply what they’ve learned to identify which of their patients are appropriate candidates for specific anti-obesity pharmacotherapies.
4. Learners will be able to explain to appropriate candidates the pros and cons of specific pharmacotherapies.

Robert F. Kushner

Professor Emeritus

Dr. Robert Kushner is a Professor Emeritus in the Departments of Medicine and Medical Education at Northwestern Feinberg School of Medicine, and former Director, Center for Lifestyle Medicine at Northwestern Medicine in Chicago, IL. He is past President of The Obesity Society (TOS) and first Chair of the American Board of Obesity Medicine (ABOM). Dr. Kushner is an internationally recognized obesity medicine clinician, educator, and clinical researcher.

The Obesity Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Obesity Society designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACCME Activity ID 202573194

Date of Release: February 1, 2024
Date of Termination: December 31, 2026

No commercial support was received for this activity.

Robert Kushner, MD: Advisor relationship with Novo Nordisk (Pharmaceuticals); WW (Medical Food and Weight Management); and Eli Lilly (Pharmaceuticals). Consultant relationship with Boehringer Ingelheim (Pharmaceuticals) and Altimmune (Pharmaceuticals). Researcher relationship with Epitomee (Medical Device).

Monica Agarwal, MD: No Relevant Financial Relationships

No members of the TOS CME Oversight Committee, charged with the resolution of all relevant conflicts of interest, had any relevant financial relationships while serving on the committee.

1. Lincoff, MA, Brown-Frandsen KB, Colhoun, HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563

2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022;387:205-216.

3. Gossmann M, Butsch WS, Jastreboff AM. Treating the Chronic Disease of Obesity. Med Clin North Am. 2021 Nov;105(6):983-1016. doi: 10.1016/j.mcna.2021.06.005. PMID: 34688422.